Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) is -72.35% lower on its value in year-to-date trading and has touched a low of $1.58 and a high of $19.95 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AMLX stock was last observed hovering at around $4.00 in the last trading session, with the day’s gains setting it 0.07%.
Currently trading at $4.07, the stock is -11.90% and -19.65% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.68 million and changing 1.75% at the moment leaves the stock 37.73% off its SMA200. AMLX registered -71.42% loss for a year compared to 6-month gain of 110.88%. The firm has a 50-day simple moving average (SMA 50) of $5.0626 and a 200-day simple moving average (SMA200) of $2.95185.
The stock witnessed a -28.09% loss in the last 1 month and extending the period to 3 months gives it a 27.19%, and is 3.30% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.41% over the week and 6.52% over the month.
Amylyx Pharmaceuticals Inc (AMLX) has around 384 employees, a market worth around $278.99M and $196.49M in sales. Profit margin for the company is -132.05%. Distance from 52-week low is 158.41% and -79.60% from its 52-week high. The company has generated returns on investments over the last 12 months (-131.84%).
The EPS is expected to shrink by -712.86% this year
155.0 institutions hold shares in Amylyx Pharmaceuticals Inc (AMLX), with institutional investors hold 96.23% of the company’s shares. The shares outstanding are 68.55M, and float is at 43.42M with Short Float at 3.61%. Institutions hold 82.47% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 4.22 million shares valued at $8.03 million. The investor’s holdings represent 6.2251 of the AMLX Shares outstanding. As of 2024-06-30, the second largest holder is AQR CAPITAL MANAGEMENT LLC with 3.34 million shares valued at $6.35 million to account for 4.9237 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 2.67 million shares representing 3.9345 and valued at over $5.07 million, while GOLDMAN SACHS GROUP INC holds 3.8471 of the shares totaling 2.61 million with a market value of $4.96 million.
Amylyx Pharmaceuticals Inc (AMLX) Insider Activity
The most recent transaction is an insider sale by Bedrosian Camille L, the company’s Chief Medical Officer. SEC filings show that Bedrosian Camille L sold 5,421 shares of the company’s common stock on Dec 02 ’24 at a price of $5.54 per share for a total of $30007.0. Following the sale, the insider now owns 0.14 million shares.
Amylyx Pharmaceuticals Inc disclosed in a document filed with the SEC on Sep 30 ’24 that Klee Justin B. (Co-Chief Executive Officer) sold a total of 18,589 shares of the company’s common stock. The trade occurred on Sep 30 ’24 and was made at $3.20 per share for $59429.0. Following the transaction, the insider now directly holds 3.12 million shares of the AMLX stock.
Still, SEC filings show that on Sep 30 ’24, Cohen Joshua B (Co-Chief Executive Officer) disposed off 18,589 shares at an average price of $3.20 for $59414.0. The insider now directly holds 3,220,569 shares of Amylyx Pharmaceuticals Inc (AMLX).
